vh 298 Search Results


vh298  (Tocris)
91
Tocris vh298
Figure 3. Hypoxia increases DOT1L and H3K79 methylation in human articular chondrocytes. (A and B) Real-time PCR for DOT1L and VEGF in C28/I2 cells treated with IOX2, <t>VH298,</t> or vehicle (V) for 72 hours (C28/I2, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in A and B, Holm corrected for 16 and 6 tests by generalized least squares model). (C) Real-time PCR in normoxic (21% O2) or hypoxic (1% O2) conditions for 6 hours (n = 3, *P < 0.05 by Welch-corrected t test). (D) Immunoblot of hypoxia-inducible factor-1 α (HIF1A), DOT1L, and H3K79 methylation after IOX2 treatment for 96 hours and in response to hypoxia. Images are representative of 2 independent experiments. (E and F) H3K79 methylation by immunofluorescence (red) and DAPI staining (blue) in C28/I2 cells after 72 hours. Images are representative of 3 independent experiments with technical duplicates. Scale bar: 50 μm. Fluorescence intensity per cell relative to V (n = 20 images per condition for each experiment; n = 3, ***P < 0.001, Holm corrected for 3 tests by generalized least squares model by generalized least squares model).
Vh298, supplied by Tocris, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vh298/product/Tocris
Average 91 stars, based on 1 article reviews
vh298 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
mc 1  (Tocris)
92
Tocris mc 1
Figure 3. Hypoxia increases DOT1L and H3K79 methylation in human articular chondrocytes. (A and B) Real-time PCR for DOT1L and VEGF in C28/I2 cells treated with IOX2, <t>VH298,</t> or vehicle (V) for 72 hours (C28/I2, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in A and B, Holm corrected for 16 and 6 tests by generalized least squares model). (C) Real-time PCR in normoxic (21% O2) or hypoxic (1% O2) conditions for 6 hours (n = 3, *P < 0.05 by Welch-corrected t test). (D) Immunoblot of hypoxia-inducible factor-1 α (HIF1A), DOT1L, and H3K79 methylation after IOX2 treatment for 96 hours and in response to hypoxia. Images are representative of 2 independent experiments. (E and F) H3K79 methylation by immunofluorescence (red) and DAPI staining (blue) in C28/I2 cells after 72 hours. Images are representative of 3 independent experiments with technical duplicates. Scale bar: 50 μm. Fluorescence intensity per cell relative to V (n = 20 images per condition for each experiment; n = 3, ***P < 0.001, Holm corrected for 3 tests by generalized least squares model by generalized least squares model).
Mc 1, supplied by Tocris, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mc 1/product/Tocris
Average 92 stars, based on 1 article reviews
mc 1 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
vh298  (BOC Sciences)
90
BOC Sciences vh298
TR-FRET binding affinity of BODIPY FL VH032 ( 5 , 1 to 2 dilutions, at an optimized concentration range of 0.06–500 nM) to GST–VCB. (A) Binding interaction of BODIPY FL VH032 ( 5 ) to 2 nM Tb-anti-GST in the presence of 2 nM GST–VCB or in the absence of GST–VCB at the designated incubation times. “+” and “–” (after each time point) represent “with GST–VCB” and “without GST–VCB”, respectively. The TR-FRET signals were expressed as relative TR-FRET units (RTU), which were calculated using 10,000 × 520 nm/490 nm. (B) Binding interaction of BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST, with 2 nM GST–VCB, 2 nM GST–VCB + <t>VH298</t> ( 2 , 30 μM), or without GST–VCB + DMSO at the 90-min incubation time. (C) Fold changes in the TR-FRET signals of BODIPY FL VH032 ( 5 ) with (2 nM GST–VCB + DMSO) to (2 nM GST–VCB + VH298) ( 2 , 30 μM) (blue curve) or to (without GST–VCB + DMSO) (red curve).
Vh298, supplied by BOC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vh298/product/BOC Sciences
Average 90 stars, based on 1 article reviews
vh298 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
vh 298 #700410  (Cayman Chemical)
90
Cayman Chemical vh 298 #700410
TR-FRET binding affinity of BODIPY FL VH032 ( 5 , 1 to 2 dilutions, at an optimized concentration range of 0.06–500 nM) to GST–VCB. (A) Binding interaction of BODIPY FL VH032 ( 5 ) to 2 nM Tb-anti-GST in the presence of 2 nM GST–VCB or in the absence of GST–VCB at the designated incubation times. “+” and “–” (after each time point) represent “with GST–VCB” and “without GST–VCB”, respectively. The TR-FRET signals were expressed as relative TR-FRET units (RTU), which were calculated using 10,000 × 520 nm/490 nm. (B) Binding interaction of BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST, with 2 nM GST–VCB, 2 nM GST–VCB + <t>VH298</t> ( 2 , 30 μM), or without GST–VCB + DMSO at the 90-min incubation time. (C) Fold changes in the TR-FRET signals of BODIPY FL VH032 ( 5 ) with (2 nM GST–VCB + DMSO) to (2 nM GST–VCB + VH298) ( 2 , 30 μM) (blue curve) or to (without GST–VCB + DMSO) (red curve).
Vh 298 #700410, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vh 298 #700410/product/Cayman Chemical
Average 90 stars, based on 1 article reviews
vh 298 #700410 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cis 6 157 hydroxynorketamine hcl  (Tocris)
86
Tocris cis 6 157 hydroxynorketamine hcl
TR-FRET binding affinity of BODIPY FL VH032 ( 5 , 1 to 2 dilutions, at an optimized concentration range of 0.06–500 nM) to GST–VCB. (A) Binding interaction of BODIPY FL VH032 ( 5 ) to 2 nM Tb-anti-GST in the presence of 2 nM GST–VCB or in the absence of GST–VCB at the designated incubation times. “+” and “–” (after each time point) represent “with GST–VCB” and “without GST–VCB”, respectively. The TR-FRET signals were expressed as relative TR-FRET units (RTU), which were calculated using 10,000 × 520 nm/490 nm. (B) Binding interaction of BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST, with 2 nM GST–VCB, 2 nM GST–VCB + <t>VH298</t> ( 2 , 30 μM), or without GST–VCB + DMSO at the 90-min incubation time. (C) Fold changes in the TR-FRET signals of BODIPY FL VH032 ( 5 ) with (2 nM GST–VCB + DMSO) to (2 nM GST–VCB + VH298) ( 2 , 30 μM) (blue curve) or to (without GST–VCB + DMSO) (red curve).
Cis 6 157 Hydroxynorketamine Hcl, supplied by Tocris, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cis 6 157 hydroxynorketamine hcl/product/Tocris
Average 86 stars, based on 1 article reviews
cis 6 157 hydroxynorketamine hcl - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier
vh-298  (MedChemExpress)
N/A
VH-298 is a highly potent inhibitor of the VHL:HIF-α interaction with a Kd value of 80 to 90 nM, used in PROTAC technology.
   Buy from Supplier
vh 298  (Biosynth Carbosynth)
N/A
A selective VHL inhibitor that stabilizes the hydroxylated form of HIF-α, resulting in upregulation of downstream target genes and proteins. Provides a tool for studying hypoxic signaling pathway.. Inhibits VHL, a tumor suppressor.
   Buy from Supplier
vh-298  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


Figure 3. Hypoxia increases DOT1L and H3K79 methylation in human articular chondrocytes. (A and B) Real-time PCR for DOT1L and VEGF in C28/I2 cells treated with IOX2, VH298, or vehicle (V) for 72 hours (C28/I2, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in A and B, Holm corrected for 16 and 6 tests by generalized least squares model). (C) Real-time PCR in normoxic (21% O2) or hypoxic (1% O2) conditions for 6 hours (n = 3, *P < 0.05 by Welch-corrected t test). (D) Immunoblot of hypoxia-inducible factor-1 α (HIF1A), DOT1L, and H3K79 methylation after IOX2 treatment for 96 hours and in response to hypoxia. Images are representative of 2 independent experiments. (E and F) H3K79 methylation by immunofluorescence (red) and DAPI staining (blue) in C28/I2 cells after 72 hours. Images are representative of 3 independent experiments with technical duplicates. Scale bar: 50 μm. Fluorescence intensity per cell relative to V (n = 20 images per condition for each experiment; n = 3, ***P < 0.001, Holm corrected for 3 tests by generalized least squares model by generalized least squares model).

Journal: JCI insight

Article Title: Hypoxia induces DOT1L in articular cartilage to protect against osteoarthritis.

doi: 10.1172/jci.insight.150451

Figure Lengend Snippet: Figure 3. Hypoxia increases DOT1L and H3K79 methylation in human articular chondrocytes. (A and B) Real-time PCR for DOT1L and VEGF in C28/I2 cells treated with IOX2, VH298, or vehicle (V) for 72 hours (C28/I2, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in A and B, Holm corrected for 16 and 6 tests by generalized least squares model). (C) Real-time PCR in normoxic (21% O2) or hypoxic (1% O2) conditions for 6 hours (n = 3, *P < 0.05 by Welch-corrected t test). (D) Immunoblot of hypoxia-inducible factor-1 α (HIF1A), DOT1L, and H3K79 methylation after IOX2 treatment for 96 hours and in response to hypoxia. Images are representative of 2 independent experiments. (E and F) H3K79 methylation by immunofluorescence (red) and DAPI staining (blue) in C28/I2 cells after 72 hours. Images are representative of 3 independent experiments with technical duplicates. Scale bar: 50 μm. Fluorescence intensity per cell relative to V (n = 20 images per condition for each experiment; n = 3, ***P < 0.001, Holm corrected for 3 tests by generalized least squares model by generalized least squares model).

Article Snippet: The hypoxia mimetics IOX2 and VH298 were purchased from MilliporeSigma and Tocris, respectively.

Techniques: Methylation, Real-time Polymerase Chain Reaction, Western Blot, Immunofluorescence, Staining, Fluorescence

TR-FRET binding affinity of BODIPY FL VH032 ( 5 , 1 to 2 dilutions, at an optimized concentration range of 0.06–500 nM) to GST–VCB. (A) Binding interaction of BODIPY FL VH032 ( 5 ) to 2 nM Tb-anti-GST in the presence of 2 nM GST–VCB or in the absence of GST–VCB at the designated incubation times. “+” and “–” (after each time point) represent “with GST–VCB” and “without GST–VCB”, respectively. The TR-FRET signals were expressed as relative TR-FRET units (RTU), which were calculated using 10,000 × 520 nm/490 nm. (B) Binding interaction of BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST, with 2 nM GST–VCB, 2 nM GST–VCB + VH298 ( 2 , 30 μM), or without GST–VCB + DMSO at the 90-min incubation time. (C) Fold changes in the TR-FRET signals of BODIPY FL VH032 ( 5 ) with (2 nM GST–VCB + DMSO) to (2 nM GST–VCB + VH298) ( 2 , 30 μM) (blue curve) or to (without GST–VCB + DMSO) (red curve).

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: TR-FRET binding affinity of BODIPY FL VH032 ( 5 , 1 to 2 dilutions, at an optimized concentration range of 0.06–500 nM) to GST–VCB. (A) Binding interaction of BODIPY FL VH032 ( 5 ) to 2 nM Tb-anti-GST in the presence of 2 nM GST–VCB or in the absence of GST–VCB at the designated incubation times. “+” and “–” (after each time point) represent “with GST–VCB” and “without GST–VCB”, respectively. The TR-FRET signals were expressed as relative TR-FRET units (RTU), which were calculated using 10,000 × 520 nm/490 nm. (B) Binding interaction of BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST, with 2 nM GST–VCB, 2 nM GST–VCB + VH298 ( 2 , 30 μM), or without GST–VCB + DMSO at the 90-min incubation time. (C) Fold changes in the TR-FRET signals of BODIPY FL VH032 ( 5 ) with (2 nM GST–VCB + DMSO) to (2 nM GST–VCB + VH298) ( 2 , 30 μM) (blue curve) or to (without GST–VCB + DMSO) (red curve).

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Binding Assay, Concentration Assay, Incubation

Signal stability of the BODIPY FL VH032 ( 5 )-based VHL TR-FRET assay. (A) TR-FRET interaction of 4 nM BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST with 2 nM GST–VCB + DMSO (negative control), 2 nM GST–VCB + VH298 ( 2 , 30 μM) (positive control), or without GST–VCB + DMSO (background control) at specified incubation time points. (B) TR-FRET signal-fold change to 2 nM GST–VCB + VH298 ( 2 , 30 μM) of 2 nM GST–VCB + DMSO (negative control), 2 nM GST–VCB + VH298 ( 2 , 30 μM) (positive control), or without GST–VCB + DMSO (background control) in the presence of 4 nM BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST at specified incubation time points. (C) Dose–response inhibition curves of VH298 ( 2 , 1–3 dilutions, in the concentration range of 2.1 pM to 30 μM) at specified incubation time points in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST.

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Signal stability of the BODIPY FL VH032 ( 5 )-based VHL TR-FRET assay. (A) TR-FRET interaction of 4 nM BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST with 2 nM GST–VCB + DMSO (negative control), 2 nM GST–VCB + VH298 ( 2 , 30 μM) (positive control), or without GST–VCB + DMSO (background control) at specified incubation time points. (B) TR-FRET signal-fold change to 2 nM GST–VCB + VH298 ( 2 , 30 μM) of 2 nM GST–VCB + DMSO (negative control), 2 nM GST–VCB + VH298 ( 2 , 30 μM) (positive control), or without GST–VCB + DMSO (background control) in the presence of 4 nM BODIPY FL VH032 ( 5 ) and 2 nM Tb-anti-GST at specified incubation time points. (C) Dose–response inhibition curves of VH298 ( 2 , 1–3 dilutions, in the concentration range of 2.1 pM to 30 μM) at specified incubation time points in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST.

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Negative Control, Positive Control, Incubation, Inhibition, Concentration Assay

Dose–response curves of a panel of VHL ligands and non-VHL ligands in the presence of BODIPY FL VH032 ( 5 , 4 nM), 2 nM GST–VCB, and 2 nM Tb-anti-GST at a 90-min incubation time. Ligand-relative TR-FRET units (RTUs) at their individual concentrations were normalized to that of VH298 ( 2 , 30 μM, positive control, 100% inhibition) and DMSO (negative control, 0% inhibition) and fitted to a sigmoidal equation with GraphPad PRISM to derive the IC 50 values, if applicable. The K i values were calculated with the Cheng–Prusoff equation. (A) Dose–response curves of VHL ligands VH032 ( 1 ), VH298 ( 2 ), VH032 amine ( 6 ), Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), and VH032 phenol ( 9 ). (B) Dose–response curves of VHL ligands VH298 ( 2 ), MZ1 ( 3 ), and VH032-PEG4-amine ( 10 ) and of non-VHL ligands (+)-JQ1 ( 4 ), thalidomide-4′-oxyacetamido-alkylC4-amine ( 11 ), and dBET1 ( 12 ).

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Dose–response curves of a panel of VHL ligands and non-VHL ligands in the presence of BODIPY FL VH032 ( 5 , 4 nM), 2 nM GST–VCB, and 2 nM Tb-anti-GST at a 90-min incubation time. Ligand-relative TR-FRET units (RTUs) at their individual concentrations were normalized to that of VH298 ( 2 , 30 μM, positive control, 100% inhibition) and DMSO (negative control, 0% inhibition) and fitted to a sigmoidal equation with GraphPad PRISM to derive the IC 50 values, if applicable. The K i values were calculated with the Cheng–Prusoff equation. (A) Dose–response curves of VHL ligands VH032 ( 1 ), VH298 ( 2 ), VH032 amine ( 6 ), Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), and VH032 phenol ( 9 ). (B) Dose–response curves of VHL ligands VH298 ( 2 ), MZ1 ( 3 ), and VH032-PEG4-amine ( 10 ) and of non-VHL ligands (+)-JQ1 ( 4 ), thalidomide-4′-oxyacetamido-alkylC4-amine ( 11 ), and dBET1 ( 12 ).

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Incubation, Positive Control, Inhibition, Negative Control

Determination of the binding affinity of BODIPY FL VH032 ( 5 , 10 nM) to GST–VCB in an FP assay with GST–VCB (1 to 2 dilutions; in the optimal concentration range of 0.03–1000 nM) + DMSO (total interactions), GST–VCB (1 to 2 dilutions; in the optimal concentration range of 0.03–1000 nM) + VH298 ( 2 , 30 μM) (i.e., GST–VCB-mediated nonspecific interactions), or DMSO without GST–VCB (i.e., background interactions) at a 90-min incubation time.

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Determination of the binding affinity of BODIPY FL VH032 ( 5 , 10 nM) to GST–VCB in an FP assay with GST–VCB (1 to 2 dilutions; in the optimal concentration range of 0.03–1000 nM) + DMSO (total interactions), GST–VCB (1 to 2 dilutions; in the optimal concentration range of 0.03–1000 nM) + VH298 ( 2 , 30 μM) (i.e., GST–VCB-mediated nonspecific interactions), or DMSO without GST–VCB (i.e., background interactions) at a 90-min incubation time.

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Binding Assay, FP Assay, Concentration Assay, Incubation

Activities of controls and selected VHL or non-VHL ligands in the BODIPY FL VH032 ( 5 )-mediated VHL FP assay with 10 nM BODIPY FL VH032 ( 5 ) and 100 nM GST–VCB at a 90-min incubation time. (A) FP assay signals of DMSO and VH298 ( 2 , 30 μM). (B) FP signal fold change from VH298 ( 2 , 30 μM) of DMSO and VH298 ( 2 , 30 μM). (C) FP dose–response curves of the VHL ligands VH032 ( 1 ), VH298 ( 2 ), VH032 amine ( 6 ), Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), and VH032 phenol ( 9 ). (D) FP dose–response curves of VH298 ( 2 ), MZ1 ( 3 ), and VH032-PEG4-amine ( 10 ) and of the non-VHL ligands (+)-JQ1 ( 4 ), thalidomide-4′-oxyacetamido-alkylC4-amine ( 11 ), and dBET1 ( 12 ).

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Activities of controls and selected VHL or non-VHL ligands in the BODIPY FL VH032 ( 5 )-mediated VHL FP assay with 10 nM BODIPY FL VH032 ( 5 ) and 100 nM GST–VCB at a 90-min incubation time. (A) FP assay signals of DMSO and VH298 ( 2 , 30 μM). (B) FP signal fold change from VH298 ( 2 , 30 μM) of DMSO and VH298 ( 2 , 30 μM). (C) FP dose–response curves of the VHL ligands VH032 ( 1 ), VH298 ( 2 ), VH032 amine ( 6 ), Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), and VH032 phenol ( 9 ). (D) FP dose–response curves of VH298 ( 2 ), MZ1 ( 3 ), and VH032-PEG4-amine ( 10 ) and of the non-VHL ligands (+)-JQ1 ( 4 ), thalidomide-4′-oxyacetamido-alkylC4-amine ( 11 ), and dBET1 ( 12 ).

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: FP Assay, Incubation

DMSO tolerance of the BODIPY FL VH032 ( 5 )-mediated VHL TR-FRET assay in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST at the 90-min incubation time point. (A) RTU of the negative control DMSO or the positive control VH298 ( 2 , 30 μM) in the presence of 0.2, 0.5, 1, 2, 5, or 10% DMSO. (B) % RTU (% RTU of 0.2% DMSO was set as 100%) of the negative control DMSO or the positive control VH298 ( 2 , 30 μM) in the presence of 0.2, 0.5, 1, 2, 5, or 10% DMSO. (C) Dose–response inhibition curves of VH298 ( 2 , 1–3 dilutions; in the concentration range of 2.1 pM to 30 μM) in the presence of indicated DMSO concentrations.

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: DMSO tolerance of the BODIPY FL VH032 ( 5 )-mediated VHL TR-FRET assay in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST at the 90-min incubation time point. (A) RTU of the negative control DMSO or the positive control VH298 ( 2 , 30 μM) in the presence of 0.2, 0.5, 1, 2, 5, or 10% DMSO. (B) % RTU (% RTU of 0.2% DMSO was set as 100%) of the negative control DMSO or the positive control VH298 ( 2 , 30 μM) in the presence of 0.2, 0.5, 1, 2, 5, or 10% DMSO. (C) Dose–response inhibition curves of VH298 ( 2 , 1–3 dilutions; in the concentration range of 2.1 pM to 30 μM) in the presence of indicated DMSO concentrations.

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Incubation, Negative Control, Positive Control, Inhibition, Concentration Assay

Pilot screening using the BODIPY FL VH032 (5)-mediated VHL TR-FRET binding assay in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST at the 90-min incubation time point. (A) Plate-by-plate negative (DMSO) and positive (VH298, 2 , 30 μM) control performance. (B) Screening scatterplot of plate Z -prime. (C) Screening scatterplot of activity values, where the positive control is VH298 ( 2 , 30 μM, green dots, 100% inhibition), the negative control is DMSO (red dots, 0% inhibition), active compounds (blue dots) are chemicals with % inhibition ≥30% with the 30% activity cutoff defined by the black dotted line, and inactive compounds (black dots) are chemicals with % inhibition <30%. (D) Chemical structures and VHL binding activities of compounds SJ000994241-1 ( 14 ), SJ000994129-1 ( 15 ), SJ000994509-1 ( 16 ), and SJ000994244-1 ( 17 ).

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Pilot screening using the BODIPY FL VH032 (5)-mediated VHL TR-FRET binding assay in the presence of 4 nM BODIPY FL VH032 ( 5 ), 2 nM GST–VCB, and 2 nM Tb-anti-GST at the 90-min incubation time point. (A) Plate-by-plate negative (DMSO) and positive (VH298, 2 , 30 μM) control performance. (B) Screening scatterplot of plate Z -prime. (C) Screening scatterplot of activity values, where the positive control is VH298 ( 2 , 30 μM, green dots, 100% inhibition), the negative control is DMSO (red dots, 0% inhibition), active compounds (blue dots) are chemicals with % inhibition ≥30% with the 30% activity cutoff defined by the black dotted line, and inactive compounds (black dots) are chemicals with % inhibition <30%. (D) Chemical structures and VHL binding activities of compounds SJ000994241-1 ( 14 ), SJ000994129-1 ( 15 ), SJ000994509-1 ( 16 ), and SJ000994244-1 ( 17 ).

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: Binding Assay, Incubation, Activity Assay, Positive Control, Inhibition, Negative Control

Comparison of a Previously Reported VHL FP Assay and Our Newly Developed VHL TR-FRET and FP Assays

Journal: ACS Omega

Article Title: Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay

doi: 10.1021/acsomega.0c05221

Figure Lengend Snippet: Comparison of a Previously Reported VHL FP Assay and Our Newly Developed VHL TR-FRET and FP Assays

Article Snippet: The VHL ligands included VH032 ( 1 ), VH298 ( 2 ), VH032 amine , Me-VH032 amine ( 7 ), BOC-VH032 ( 8 ), VH032 phenol ( 9 ), VH032-PEG4-amine ( 10 ), and the dual VHL and BRD PROTAC ligand MZ1 ( 3 ).

Techniques: FP Assay, Concentration Assay